Pioneer in phage-based diagnostics

01359 231856

Twitter Youtube Linkedin Envelope
  • Home
  • About
    • About PBD Biotech
    • Leadership
    • Blog
  • Latest
    • Press releases
    • In the news
    • Events
  • Actiphage TB
    • What is Actiphage TB?
    • Unique role in TB testing
    • Supporting test and treat campaigns
    • Clinical studies
  • Lab Support
    • Laboratory Support
    • Solutions for laboratory developed tests
    • Actiphage assay workflow
    • Instructions for use of Actiphage
  • TB Drug Research
    • TB drug research
    • Research Use Only
    • Biomarker for TB prevention
  • Contact
    • Contacting us
    • Partnerships and collaborations
Menu
  • Home
  • About
    • About PBD Biotech
    • Leadership
    • Blog
  • Latest
    • Press releases
    • In the news
    • Events
  • Actiphage TB
    • What is Actiphage TB?
    • Unique role in TB testing
    • Supporting test and treat campaigns
    • Clinical studies
  • Lab Support
    • Laboratory Support
    • Solutions for laboratory developed tests
    • Actiphage assay workflow
    • Instructions for use of Actiphage
  • TB Drug Research
    • TB drug research
    • Research Use Only
    • Biomarker for TB prevention
  • Contact
    • Contacting us
    • Partnerships and collaborations

Management Team

The PBD Biotech international management team brings together expertise in diagnostics, clinical and veterinary science, disease management and policy.

Board

Loading...
Marie Roskrow

Dr Marie Roskrow,

Chair of the Board

Marie Roskrow is an experienced physician-scientist and a senior executive with international experience in the healthcare and financial sectors. Her extensive experience includes early- and later-stage clinical development of novel anti-cancer compounds and the development of a novel therapeutic vaccine and complementary rapid diagnostic test for the treatment of patients with resistant Helicobacter pylori. She has held roles as CEO, CMO and Chairperson in private and listed companies, and has an extensive network of relationships with investors, senior executives and board members of healthcare companies and leading clinical centres both in Europe and the USA.
Jane Theaker, CEO, PBD Biotech (c) Chelsea Shoesmith Photography - square

Jane Theaker,

Chief Executive Officer

Jane Theaker has a strong track record in precision medicine and novel diagnostics technologies. Her experience includes genomics with AstraZeneca and the co-invention of a new quantitative PCR technology. She headed up a team at Qiagen developing diagnostics kits to FDA standards before joining LGC as VP of R+D within genomics and establishing a precision medicine consultancy DataGC Solutions Ltd.
Tom Green

Tom Green,

Non-Executive Director

Following a career in vertically integrated production agriculture, farming over 85,000 hectares in UK and Europe as CEO of Spearhead International, Tom is now focussing on the theme of ‘Agritech to drive farm performance and sustainability’. Continuing as an NED at Spearhead, Tom holds roles at UK agriculture companies including Metos UK, Cambridge Agritech, Hummingbird Technologies, as well as with the charity LEAF.

Dr Berwyn Clarke,

Non-Executive Director

Berwyn is a specialist in personalized medicine, companion diagnostics and the application of novel diagnostics both to central laboratory and point-of-care utilities. He has worked in the pharmaceutical and diagnostics industry for over 30 years occupying senior management positions and Board level appointments. He is now a commercially focused entrepreneur with multiple corporate appointments.
Jonnie Yewdall

Jonnie Yewdall,

Chief Commercial Officer, UK and international

Jonnie joined PBD Biotech as its Commercial Director in 2020 and has held a number of commercial roles in other industries. He ran a farm in North Devon and as a dairy farmer he understands the challenges of the industry and has first-hand experience of the devastating impact bTB and Johne’s disease.
Sandy Reid

Sandy Reid,

Investor Director

Sandy Reid is Deputy Fund Principal at Mercia Asset Management where she has worked for six years. Her portfolio includes life science, tech and software investments with a focus on early-stage businesses in the Midlands. She also has broader responsibility for fund strategy, reporting and investor relations in the Midlands. Prior to working at Mercia Sandy worked as a consultant and Director to a number of early-stage businesses and was CEO of a VC backed business for eight years. She also holds a PhD in Chemistry and is a Fellow of the Royal Society of Chemistry.
Geoff Gower, Operations Director, PBD Biotech

Geoff Gower,

Non-Executive Director

Geoff has a significant track record in diagnostic manufacturing and joined PBD Biotech to oversee the scale-up of Actiphage from a research to a commercial environment. Geoff has an impressive track-record of building start-ups to become market leaders in their niche. Several have subsequently been acquired by companies such as Thermo Fisher Scientific and Bio-Rad.

Executive Team

Loading...
Jane Theaker, CEO, PBD Biotech (c) Chelsea Shoesmith Photography - square

Jane Theaker,

Chief Executive Officer

Jonnie Yewdall

Jonnie Yewdall,

Chief Commercial Officer, UK and international

Mondana Cook, Chief Operating Officer at PBD Biotech

Mondana Cook,

Chief Operating Officer

Mondana has a significant track record of managing complex projects and translating new technologies into successful commercial products. Her previous positions include COO at precision medicine company Kinomica, and Director of Program Management at QIAGEN, where she led the R&D of blood biomarker companion diagnostics, delivering projects (+$100M) with multiple product approvals. She has a deep understanding of the TB challenge - as Program Manager for the Oxford Emergent Tuberculosis Consortium (OETC) she was involved in the development of a novel TB vaccine.
Joely Irlam, PBD Biotech CTO

Joely Irlam,

Chief Technology Officer

Joely has more than 25 years' cancer research experience at the Christie Hospital and University of Manchester, and she has 16 years’ experience in developing, validating, and delivering hypoxia-associated biomarkers. She is a technical expert in clinical biomarker platform discovery, co-founding university spin-out company ManTRa Diagnostics Ltd, for which she also served as CEO, to deliver a genomic test for precision cancer treatments and improved patient outcomes. Joely is also involved in a steering group (Biomedical research Engagement Academic clinical healthcare – BREACH) to encourage academic/industrial engagement, helping to drive academic science across the translational gap for cancer patient benefit.
Durga Devi Nilojan, Financial Controller

Durga Nilojan,

Finance Officer

Durga is a finance controller with international experience. She joins us from InnuScience, a global leader in commercial cleaning solutions based on biotechnology.
Douglas McKechnie, QA Manager

Douglas McKechnie,

Quality Assurance Manager

Dougie McKechnie started his career as a molecular biologist in contract research before joining ICI Pharmaceuticals to set up DNA fingerprinting business Cellmark Diagnostics. He then moved into quality assurance, gaining ISO 9001 and ISO 17025 for Cellmark. Moving to human tissue banking, he gained experience in HT Act and NRES in AstraZeneca’s Global Biobank. Latterly, he gained ISO 15189 accreditation for the Alderley Park Lighthouse Lab, one of the UKHSA’s largest COVID-19 testing facilities. Dougie has now joined PBD Biotech as Quality Assurance Manager and will be working towards accreditation for ISO 13485.

Scientific Advisory Board

Loading...
Jane Theaker, CEO, PBD Biotech (c) Chelsea Shoesmith Photography - square

Jane Theaker,

Chief Executive Officer

Berwyn Clarke

Dr Berwyn Clarke,

Non-Executive Director

Ben Swift

Dr Ben Swift,

Research Fellow in Antimicrobial Resistance, Royal Veterinary College

Ben is currently a Research Fellow in Antimicrobial Resistance at the Royal Veterinary College. His work, in collaboration with Cath Rees led to the creation of the Actiphage diagnostic. He continues to be involved in developing rapid detection methods for mycobacterial diseases, with a special interest in the transmission of mycobacterial pathogens between humans and animals, working closely with both vets and medical doctors.
Cath Rees

Prof Cath Rees,

Professor in Microbiology, University of Nottingham

As Professor in Microbiology at the University of Nottingham, Prof Rees leads research into the applications of bacteriophage against cattle pathogens Mycobacterium paratuberculosis (Johne's disease) and Mycobacterium bovis (bovine TB). This work led to the creation of the Actiphage diagnostic and forms the basis for its continued development.
Dr Pranab Haldar

Dr Pranab Haldar,

Lead Physician for Clinical TB services, University of Leicester

Pranab Haldar is an Associate Clinical Professor of Respiratory Medicine and Lead Physician for Clinical TB services at Leicester, one of the largest TB Centres in the UK. His primary academic interest is the phenotypic characterisation of human M. tuberculosis infection to support development of novel approaches and clinical tools for improving care of patients with TB. His clinical research work is based at the NIHR Respiratory Biomedical Centre at Glenfield Hospital that provides an integrated clinical-research platform to support prospective cohort studies evaluating novel host immune and pathogen-directed biomarkers of TB infection that are being developed in collaboration with academic colleagues at the Francis Crick Institute and University of Nottingham.
Delia Goletti

Delia Goletti,

Head of the Translational Research Unit, INMI

Delia Goletti is the Head of the Translational Research Unit at the National Institute for Infectious Diseases L. Spallanzani-IRCCS (INMI) in Rome, Italy. She has also clinical duties at the outpatient’s clinic for the Respiratory Infectious Diseases Unit of INMI. Her current research interests are on the immune pathogenesis, immune diagnostic tests and host directed therapies for tuberculosis, echinococcosis and COVID-19.
Robert Price-Jones

Robert Price-Jones,

Clinical Director, Tysul Vets

Robert Price-Jones BSc(Hons) BVSc MRCVS graduated from Liverpool University in 1991 with a Bachelors in Veterinary Science and a 1st Class Honours in Genetics, and has been a large animal vet for 22 years. Robert is Clinical Director of Tysul Vets, a Veterinary Practice based in West Wales which resides within a bTB High Risk area and was the first to trial Actiphage as a diagnostic tool in cattle within Wales. Having experienced the relentless spread of bTB in the area, Robert has developed a particular interest in biosecurity as well as the epidemiology and diagnosis of bTB.

developers of phage-based diagnostics

Contact Us
BIVDA member 2023

Registered Company Address
Grosvenor St Paul’s
Grosvenor House
11 St Paul’s Square
Birmingham
B3 1RB
United Kingdom

T: 01359 231856
info@pbdbio.com

Privacy and cookies policy

© 2022 PBD Biotech Ltd

design: out of house

  • Follow Us!